Documents to download

The Access to Medical Treatments (Innovation) Bill is a private member’s bill introduced by Chris Heaton-Harris (Conservative MP for Daventry) and sponsored in the House of Lords by Lord Saatchi (Conservative). The Bill completed its House of Commons stages on 29 January 2016 and received its first reading in the House of Lords on 1 February 2016. It is expected to receive its second reading in the House of Lords on 26 February 2016.  

The purpose of the Bill is to promote access to innovative medical treatments by providing for the establishment of a database of innovative medical treatments, and access to that database. When it was introduced in the House of Commons, the Bill also contained two clauses concerning medical negligence which set out the steps a doctor would need to take in order to show that he or she has acted responsibly in giving innovative treatment.  These clauses were removed during report stage in the House of Commons.  These two clauses were largely the same as those contained in the Medical Innovation Bill [HL], which was introduced by Lord Saatchi in the House of Lords on 8 June 2015 and has yet to receive a second reading.

Documents to download

Related posts

  • The Government has announced that the England-wide Covid-19 restrictions commonly referred to as ‘lockdown 2’ will not be renewed past 2 December 2020. The restrictions are to be replaced with a revised tier structure for England similar to the one in place before the second lockdown. The revised tiers form part of the Government’s Winter Plan, which was announced on 23 November 2020.

  • Medicinal and agrochemical products can be granted a Supplementary Protection Certificate, an intellectual property right associated with patents, to provide up to five years of additional rights and protections once their patents have expired. In order to apply for an SPC, a product must receive approval to be sold on the UK market. Under the Northern Ireland/Ireland Protocol, products to be sold in Northern Ireland must obtain approval under EU law, whilst products to be sold in the rest of the UK will obtain approval under UK law. Currently, this marketing authorisation is only given on a UK-wide basis. This regulation amends the market authorisation process to enable authorisations to be granted for the Northern Ireland market only and for the Great Britain market only.

  • There is currently a system for mutual recognition of health and social care qualifications within and between European Economic Area states and Switzerland. The UK has passed legislation amending its provisions in this area to take account of its exit from the EU. In recent agreements with Switzerland and the European Free Trade Area states, the UK committed to conditions for these countries which go further than the legislation that has already been passed. The European Qualifications (Health and Social Care Professions) (EFTA States) (Amendment etc.) (EU Exit) Regulations 2020 would implement these commitments.